Life sciences · Journal article
Angewandte Chemie International Edition · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Conventional antibacterial vaccines often fail to elicit robust immunity against multifaceted virulence factors, including bacterial surface antigens and secreted toxins, particularly lacking the strong T‐cell responses essential for effective infection prevention. To overcome this limitation, we engineered dendritic cell (DC) membrane‐derived nanodiscs (aDCNDs) with stiffness‐tuned topology as a mechanoimmunological antibacterial nanovaccine. aDCNDs uniquely co‐present multi‐antigens from bacterial membranes and secreted toxins alongside upregulated immune‐stimulatory molecules, eliciting potent adaptive immunity that simultaneously targets Pseudomonas aeruginosa cells and neutralizes cytotoxic exotoxins for dual protection. Their precisely controlled sub‐50 nm size enables superior lymph node accumulation versus larger nanovesicles. Importantly, aDCNDs engage T cell mechanotransduction to promote TAZ nuclear translocation, augmenting T cell activation and the secretion of IFN‐γ, IL‐17A, and IL‐4, an effect not observed with conventional soft nanovesicles. The increased stiffness of aDCNDs represents an important and likely contributor to this mechano‐stimulatory effect. In lethal murine models of septicemia and pneumonia, aDCNDs vaccination achieved profound reductions in bacterial burdens (up to 99.99%) and markedly improved survival without systemic toxicity. This work establishes the aDCND platform as a safe and effective antibacterial strategy, highlighting mechano‐immunology as a critical design principle for next‐generation antibacterial vaccines.